Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells

被引：0
|
作者：
Atefeh Sharifhoseini
Masoud Heshmati
Amin Soltani
Mahshad Entezam
Hedayatollah Shirzad
Morteza Sedehi
Babri A. Judd
Mohammad-Saeid Jami
Mahdi Ghatrehsamani
机构：
[1] Shahrekord University of Medical Sciences,Cellular and Molecular Research Center
[2] Shahrekord University of Medical Sciences,Department of Microbiology and Immunology
[3] Shahrekord University of Medical Sciences,Department of Epidemiology and Biostatistics, School of Health
[4] Immunology Science Editors,Department of Neurology, David Geffen School of Medicine
[5] University of California Los Angeles (UCLA),undefined
来源：
Molecular Biology Reports | 2023年 / 50卷
关键词：
Breast cancer; BET inhibitor; JQ1; IL-6; Breast cancer stem cell; CXCR4;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：8319 / 8328
页数：9
相关论文
共 50 条
  • [1] Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells
    Sharifhoseini, Atefeh
    Heshmati, Masoud
    Soltani, Amin
    Entezam, Mahshad
    Shirzad, Hedayatollah
    Sedehi, Morteza
    Judd, Babri A.
    Jami, Mohammad-Saeid
    Ghatrehsamani, Mahdi
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (10) : 8319 - 8328
  • [2] Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
    Li, Feng
    MacKenzie, Kevin R.
    Jain, Prashi
    Santini, Conrad
    Young, Damian W.
    Matzuk, Martin M.
    BIOLOGY OF REPRODUCTION, 2020, 103 (02) : 427 - 436
  • [3] Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells
    Baldan, Federica
    Allegri, Lorenzo
    Lazarevic, Milos
    Catia, Mio
    Milosevic, Maja
    Damante, Giuseppe
    Milasin, Jelena
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2019, 48 (03) : 214 - 221
  • [4] Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension
    Mumby, Sharon
    Gambaryan, Natalia
    Meng, Chao
    Perros, Frederic
    Humbert, Marc
    Wort, S. John
    Adcock, Ian M.
    RESPIROLOGY, 2017, 22 (01) : 157 - 164
  • [5] Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells
    Ghurye, Rohit R.
    Stewart, Helen J. S.
    Chevassut, Timothy J.
    CYTOKINE, 2015, 71 (02) : 415 - 417
  • [6] Characterisation of the effects of BET inhibitor JQ1 on c-Myc and interleukin-6 in multiple myeloma cells
    Ghurye, R. R.
    Stewart, H. J. S.
    Chevassut, T. J.
    IMMUNOLOGY, 2014, 143 : 123 - 123
  • [7] Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1
    Zhang, Chengyue
    Su, Zheng-Yuan
    Wang, Ling
    Shu, Limin
    Yang, Yuqing
    Guo, Yue
    Pung, Douglas
    Bountra, Chas
    Kong, Ah-Ng
    BIOCHEMICAL PHARMACOLOGY, 2016, 117 : 35 - 45
  • [8] BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells
    Mio, Catia
    Conzatti, Ketty
    Baldan, Federica
    Allegri, Lorenzo
    Sponziello, Marialuisa
    Rosignolo, Francesca
    Russo, Diego
    Filetti, Sebastiano
    Damante, Giusepe
    ONCOLOGY REPORTS, 2018, 39 (02) : 582 - 588
  • [9] The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway
    Lei, Linping
    Xie, Xuqin
    He, Long
    Chen, Keling
    Lv, Zhaoying
    Zhou, Bin
    Li, Yuan
    Hu, Wenjun
    Zhou, Zongguang
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 362 - 376
  • [10] The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway
    Linping Lei
    Xuqin Xie
    Long He
    Keling Chen
    Zhaoying Lv
    Bin Zhou
    Yuan Li
    Wenjun Hu
    Zongguang Zhou
    Investigational New Drugs, 2021, 39 : 362 - 376
12345